In the United States, pharmaceutical advertising seems inescapable.
Since the first prescription drug ad ran in the early 1980s, the business of pharmaceutical advertising has exploded. Drug companies spent $7 billion on advertising last year, according to Statista, with most of that going to television ads; more than $287 million was spent on TV advertising for Sanofi and Regeneron’s anti-inflammatory drug Dupixent alone.
Yet most people would rather not see these ads at all. In a 2016 STAT-Harvard T.H. Chan poll, more than half of the people surveyed — 57%, to be precise — wanted drug ads to be taken off the air.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect